PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
Texas A&M Study Highlights Pictor PictVet® as a Promising New Tool for Non-Invasive Beef Cattle Health Monitoring
Independent peer-reviewed research published in Frontiers in Veterinary Science reports strong assay performance in a proof-of-concept evaluation using bovine nasopharyngeal swab samples ...
2026-06-23T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
CJ BIO to Showcase TasteNrich® Taste Lab for Sodium Reduction, Clean Label, and Taste Design Solutions at IFT FIRST 2026
"Not Just Reducing, But Designing Better Taste" ...
2026-06-22T    Biotechnology   Health Care/Hospital   Retail 
Biomerics Appoints Kristin Mason as Chief Financial Officer
SALT LAKE CITY , June 22, 2026 /PRNewswire/ -- Biomerics, a leading vertically integrated contract manufacturer for the interventional medical device market, today announced the appointment of Kristin ...
2026-06-22T    Computer/Electronics   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
ACEMATE Tennis Robot S10 Gets $600 Prime Day Discount, with Bonus Gifts
HONG KONG , June 22, 2026 /PRNewswire/ --  ACEMATE today announced a Prime Day promotion for the Acemate S10, its flagship AI tennis robot built for real-rally practice. From June 23 through ...
2026-06-22T    Computer/Electronics   Health Care/Hospital   Retail   Sports 
Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)
European approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 demonstrated a statistically significant improvement ...
2026-06-22T    Health Care/Hospital   Medical/Pharmaceuticals 
Sisram Medical Bolsters EBD and Injectables in Thailand to Unlock APAC Growth
With advancing EBD rollout and steady injectables expansion, integrated treatment protocols deliver unique competitive edges for high-quality regional growth ...
2026-06-22T    Cosmetics & Personal Care   Health Care/Hospital   Household/Consumer/Cosmetics   Medical/Pharmaceuticals 
Sisram Medical Bolsters EBD and Injectables in Thailand to Unlock APAC Growth
With advancing EBD rollout and steady injectables expansion, integrated treatment protocols deliver unique competitive edges for high-quality regional growth ...
2026-06-22T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI , June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the ...
2026-06-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI , June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the ...
2026-06-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
ChemT Biotechnology Raises US$5 Million in 18 months to bring AI to Biomanufacturing
The total funding comprises US$1 million in angel investment and a US$4 million seed round. The seed financing round was led by Wavemaker Ventures, with participation by SEEDS, further supported by notable ...
2026-06-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.